Concepedia

Author

D. Frye

The University of Texas MD Anderson Cancer Center

Also Known As

D Frye, D K Frye, D. Frye, D. K. Frye, Dennis Frye

29

Publications

2.5K

Citations

13

H-Index

16

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterBreast Cancer Care
DF

About

D. Frye is an author at The University of Texas MD Anderson Cancer Center specializing in cancer therapeutics, oncology, and breast cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

1.1K

2

Cancer Therapeutics

6

6

1.1K

3

Pharmacology

5

5

1K

4

Health Sciences

3

3

215

5

Obstetrics

1

1

74

D. Frye

×

14

Publications

2.4K

Citations

13

H-Index

YearCitations

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

Philip Greenberg, Gabriel N. Hortobágyi, Terry L. Smith,

Journal of Clinical Oncology

1996

753

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

Frankie A. Holmes, R S Walters, R. Theriault,

JNCI Journal of the National Cancer Institute

1991

745

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

Gabriel N. Hortobágyi, D. Frye, Aman U. Buzdar,

Cancer

1989

199

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.

Zillur Rahman, D. Frye, Aman U. Buzdar,

Journal of Clinical Oncology

1997

155

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.

Gabriel N. Hortobágyi, Gerald P. Bodey, Aman U. Buzdar,

Journal of Clinical Oncology

1987

129

Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.

Eleni Diamandidou, Aman U. Buzdar, Terry L. Smith,

Journal of Clinical Oncology

1996

124

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers

Chafika Mazouni, Shu‐Wan Kau, D. Frye,

Annals of Oncology

2007

74

Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy

Raj K. Maturi, Adam R. Glassman, Kristin Josic,

JAMA

2023

53

The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.

Frankie A. Holmes, Vicente Valero, Ronald S. Walters,

PubMed

1993

49

Capecitabine: nursing implications of a new oral chemotherapeutic agent.

M Mrozek-Orlowski, D. Frye, H M Sanborn

PubMed

1999

44

Page 1